Fluorometholone + Tetrahydrozoline interactions
Checked as Fluorometholone + Tetryzoline (ophthalmic) in this data source.
Full monograph for Fluorometholone + TetrahydrozolineCheck it against another medicine
Medicines
53 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Ergometrine Maleatevia Tetryzoline (ophthalmic) | Major | Synergy | Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central… | 38 sources — open the full entry |
| Methylergonovine Maleatevia Tetryzoline (ophthalmic) | Major | Synergy | Additive or synergistic increases in blood pressure and/or ischemic response may occur when ergot alkaloids are combined with peripheral or central… | 38 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Arformoterol Tartratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrroniumvia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Budesonide + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Bupropion Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Translated with DeepL | 4 sources — open the full entry |
| Desvenlafaxine Succinatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Dextromethorphan + Bupropionvia Tetryzoline (ophthalmic) | Moderate | Synergy | Translated with DeepL | 4 sources — open the full entry |
| Duloxetine Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Fluticasone Propionate + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Formoterol Fumarate + Glycopyrrolate + Budesonidevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Glycopyrronium Bromide + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol + Glycopyrroniumvia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol + Glycopyrronium + Mometasone Furoatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Indacaterol Maleatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Ketamine Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Ketamine can cause hemodynamic instability such as arrhythmias and transient increases or decreases in blood pressure, heart rate, and cardiac index… | 7 sources — open the full entry |
| Levomilnacipran Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| LevosalbutamolOralRespirator preparationvia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Linezolidvia Tetryzoline (ophthalmic) | Moderate | Synergy | By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically… | 34 sources — open the full entry |
| Milnacipran Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Mometasone Furoate + Formoterol Fumaratevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Racepinephrinevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Rasagilinevia Tetryzoline (ophthalmic) | Moderate | Synergy | By inhibiting the breakdown of catecholamines, monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of systemically… | 34 sources — open the full entry |
| Ritodrine Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Safinamide Mesylatevia Tetryzoline (ophthalmic) | Moderate | Metabolism | Monoamine oxidase inhibitors (MAOIs) may theoretically potentiate the cardiovascular effects of sympathomimetic agents following oral and/or topical… | 20 sources — open the full entry |
| SalbutamolbaseInhalervia Tetryzoline (ophthalmic), Fluorometholone | Moderate | Synergy · Unknown | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 11 sources — open the full entry |
| Salbutamol + Budesonidevia Tetryzoline (ophthalmic), Fluorometholone | Moderate | Synergy · Unknown | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 11 sources — open the full entry |
| Salbutamol + IpratropiumInhalerSolution for inhalationvia Tetryzoline (ophthalmic), Fluorometholone | Moderate | Synergy · Unknown | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists…2 documented mechanisms | 11 sources — open the full entry |
| Salmeterol + Fluticasone Propionatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Salmeterol Xinafoatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Tapentadol Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
| Terbutaline Sulfatevia Tetryzoline (ophthalmic) | Moderate | Synergy | Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists… | 11 sources — open the full entry |
| Venlafaxine Hydrochloridevia Tetryzoline (ophthalmic) | Moderate | Synergy | Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with… | 12 sources — open the full entry |
This source documents no food, condition or duplication entries for Fluorometholone + Tetrahydrozoline.